Physician profile
Daniel Kitner
NPI 1619430790
$1,862.41
in general payments reported to CMS, 2019-2025
17 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $265 · 2023: $983 · 2024: $500 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $500.00 | 2024 | |
| Abbvie INC. | $217.11 | 2022-2023 | |
| Novo Nordisk INC | $208.63 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $145.16 | 2022-2023 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $140.90 | 2022-2023 | Farxiga, Breztri |
| Exact Sciences Corporation | $121.62 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $112.02 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $72.61 | 2023 | Spravato |
| Pfizer INC. | $69.02 | 2023 | |
| Glaxosmithkline, LLC. | $58.73 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Dynavax Technologies Corporation | $55.25 | 2022-2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $39.93 | 2022 | |
| Xeris Pharmaceuticals, INC. | $34.60 | 2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $28.49 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.40 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $18.30 | 2023 | Immunocap |
| Hologic Sales and Service, LLC | $16.64 | 2023 | Aptima, Thinprep 2000 Processor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kitner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.